Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
BDSX Biodesix Inc
- Stocks
- Healthcare
- NASDAQ: BDSX
Price (delayed)
$0.2837
Market cap
$41.58M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.28
Enterprise value
$86.26M
Biodesix, Inc. operates as a biotechnology company. The Company offers non-small cell lung cancer pretreatment serum tests and laboratory testing. Biodesix provides diagnostic tools and equipment for blood and tissue
Highlights
BDSX's EPS is up by 48% year-on-year and by 15% since the previous quarter
The company's gross profit rose by 40% YoY and by 4.7% QoQ
Biodesix's quick ratio has soared by 179% YoY but it has decreased by 22% from the previous quarter
The equity has declined by 47% since the previous quarter
Key stats
What are the main financial stats of BDSX
Market
Valuations
Earnings
Shares outstanding
146.56M
Market cap
$41.58M
Enterprise value
$86.26M
Price to earnings (P/E)
N/A
Price to book (P/B)
3.74
Price to sales (P/S)
0.56
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.16
Revenue
$74.46M
Gross profit
$58.36M
Operating income
-$32.61M
Net income
-$40.42M
EBIT
-$33M
EBITDA
-$27.11M
Free cash flow
-$45.24M
Per share
Balance sheet
Liquidity
EPS
-$0.28
EPS diluted
-$0.28
Free cash flow per share
-$0.31
Book value per share
$0.08
Revenue per share
$0.51
TBVPS
$0.45
Total assets
$86.24M
Total liabilities
$75.18M
Debt
$62.29M
Equity
$11.06M
Working capital
$16.31M
Debt to equity
5.63
Current ratio
2.22
Quick ratio
1.9
Net debt/EBITDA
-1.65
Margins
Efficiency
Dividend
EBITDA margin
-36.4%
Gross margin
78.4%
Net margin
-54.3%
Operating margin
-43.8%
Return on assets
-40.2%
Return on equity
-168.3%
Return on invested capital
-33.9%
Return on capital employed
-45.3%
Return on sales
-44.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
BDSX stock price
How has the Biodesix stock price performed over time
Intraday
13.34%
1 week
5.58%
1 month
-6.06%
1 year
-81.46%
YTD
-81.46%
QTD
-54.62%
Financial performance
How have Biodesix's revenue and profit performed over time
Revenue
$74.46M
Gross profit
$58.36M
Operating income
-$32.61M
Net income
-$40.42M
Gross margin
78.4%
Net margin
-54.3%
The company's gross profit rose by 40% YoY and by 4.7% QoQ
BDSX's net margin is up by 37% YoY and by 10% QoQ
Biodesix's revenue has increased by 36% YoY and by 4.4% QoQ
The operating margin has increased by 33% year-on-year and by 10% since the previous quarter
Price vs fundamentals
How does BDSX's price correlate with its fundamentals
Growth
What is Biodesix's growth rate over time
Valuation
What is Biodesix stock price valuation
P/E
N/A
P/B
3.74
P/S
0.56
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.16
BDSX's EPS is up by 48% year-on-year and by 15% since the previous quarter
The stock's price to book (P/B) is 60% less than its last 4 quarters average of 8.3
The equity has declined by 47% since the previous quarter
The price to sales (P/S) is 84% lower than the 5-year quarterly average of 3.0 and 83% lower than the last 4 quarters average of 2.8
Biodesix's revenue has increased by 36% YoY and by 4.4% QoQ
Efficiency
How efficient is Biodesix business performance
BDSX's ROIC is up by 38% YoY and by 8% QoQ
BDSX's ROS is up by 35% year-on-year and by 9% since the previous quarter
BDSX's return on assets is up by 25% year-on-year and by 6% since the previous quarter
The ROE is up by 22% QoQ
Dividends
What is BDSX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for BDSX.
Financial health
How did Biodesix financials performed over time
The company's total assets is 15% higher than its total liabilities
Biodesix's quick ratio has soared by 179% YoY but it has decreased by 22% from the previous quarter
The company's current ratio has surged by 144% YoY but it fell by 20% QoQ
The debt to equity has soared by 151% year-on-year and by 90% since the previous quarter
The equity has declined by 47% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.